Description
Catalent is a leading global CDMO headquartered in Tampa, Florida, a subsidiary of Novo Holdings A/S (acquired for $16.5B in 2024). With 50+ facilities on four continents, it annually produces 70 billion doses for 8,000 products. It offers integrated solutions in oral dose, biologics, cell & gene therapy, and clinical supply, plus proprietary technologies like Zydis® (fast-dissolving tablets). It has supported more than half of all FDA-approved products in the past decade.